SR ONE CAPITAL MANAGEMENT, LP Long-Term Concentrated

CIK: 0001910264 · Show all filings

Period: Q1 2024 (← Previous) (Next →)

Filing Date: May 13, 2024

Total Value ($000): $364,089 (100.0% shares, 0.0% debt)

Holdings (6)

ACLX ARCELLX INC 44.8%

Value ($000) $163,208 Shares 2,346,630 Est. Cost $16.72 Unrealized +279.3%

CRSP CRISPR THERAPEUTICS AG 19.6%

Value ($000) $71,497 Shares 1,048,951 Est. Cost $71.59 Unrealized 0.0%

SPRY ARS PHARMACEUTICALS INC 11.3%

Value ($000) $41,012 Shares 4,012,903 Est. Cost $6.79 Unrealized +9.9%

NKTX NKARTA INC 9.9%

Value ($000) $36,033 Shares 3,333,333 Est. Cost $11.49 Unrealized -9.5%

DSGN DESIGN THERAPEUTICS INC 7.2%

Value ($000) $26,302 Shares 6,526,476 Est. Cost $16.67 Unrealized -84.0%

MLYS MINERALYS THERAPEUTICS INC 7.2%

Value ($000) $26,037 Shares 2,016,822 Est. Cost $16.34 Unrealized -24.4%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ACLX	ARCELLX INC	2,346,630	$163,208	44.8%	$16.72	+279.3%	COMMON STOCK	03940C100
CRSP	CRISPR THERAPEUTICS AG	1,048,951	$71,497	19.6%	$71.59	0.0%	NAMEN AKT	H17182108
SPRY	ARS PHARMACEUTICALS INC	4,012,903	$41,012	11.3%	$6.79	+9.9%	COM	82835W108
NKTX	NKARTA INC	3,333,333	$36,033	9.9%	$11.49	-9.5%	COM	65487U108
DSGN	DESIGN THERAPEUTICS INC	6,526,476	$26,302	7.2%	$16.67	-84.0%	COM	25056L103
MLYS	MINERALYS THERAPEUTICS INC	2,016,822	$26,037	7.2%	$16.34	-24.4%	COM	603170101